Periodic Reporting for period 1 - PReDicT (Predicting Response to Depression Treatment)
Período documentado: 2015-02-01 hasta 2015-05-31
The Phase 1 feasibility project has enabled us to confirm the need for better tools, such as the eH-ETB, to manage the treatment of depression in Europe and worldwide. The impact that the eH-ETB can have on reducing the burden of depression on patients, healthcare and society, and the market opportunity for the commercialisation of the eH-ETB in Europe, US and the rest of the world is significant. The Phase 1 work has confirmed that P1vital should move ahead with this project and secure Horizon 2020 Phase 2 funding to complete the development activities of the eH-ETB to enable product launch.
In summary, the unique selling points of the eH-ETB are that it: (i) will improve response and remission rates and shorten functional disability, impacting both patients and their families in their social and working lives. (ii) has the potential to significantly reduce both healthcare and societal costs. (iii) will significantly reduce ineffective prescribing of antidepressants and the associated side effects, by identifying non-response early in treatment.